



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: LYGEMOXPEG

(Page 1 of 3)

DOCTOR'S ORDERS	Ht _____ cm	Wt _____ kg	BSA _____ m ²
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form			
DATE:	To be given:	Cycle #:	
Date of Previous Cycle: _____			
<input type="checkbox"/> Delay treatment _____ week(s) <input type="checkbox"/> CBC & Diff and platelets day 1 of treatment Day 1: May proceed with doses as written, if within 72 hours ANC greater than or equal to 1.0 x 10⁹/L, Platelets greater than or equal to 75 x 10⁹/L, creatinine clearance greater than or equal to 50 mL/minute, direct bilirubin less than 51 micromol/L, ALT less than or equal to 5 times upper limit of normal Day 8: May proceed with doses as written, if within 48 hours ANC greater than or equal to 1.0 x 10⁹/L, Platelets greater than or equal to 75 x 10⁹/L Dose modification for: <input type="checkbox"/> Hematology <input type="checkbox"/> Other Toxicity _____ Proceed with treatment based on blood work from _____			
PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm _____.			
<u>DAY 1</u>			
ondansetron 8 mg PO prior to treatment.			
dexamethasone <input type="checkbox"/> 8 mg or <input type="checkbox"/> 12 mg PO (select one) prior to treatment.			
<input type="checkbox"/> Other:			
<u>Prior to pegaspargase:</u>			
acetaminophen 650 mg PO			
diphenhydrAMINE <input type="checkbox"/> 25 mg or <input type="checkbox"/> 50 mg (select one) <input type="checkbox"/> PO or <input type="checkbox"/> IV (select one)			
hydrocortisone 100 mg IV			
If fibrinogen less than 0.5 g/L:			
<input type="checkbox"/> fibrinogen concentrate 4 g IV prior to pegaspargase (complete transfusion medicine order).			
Refer to protocol for guidance regarding pegaspargase.			
NO ice chips.			
<u>DAY 8</u>			
<input type="checkbox"/> prochlorperazine 10mg PO or <input type="checkbox"/> metoclopramide 10mg PO prior to treatment			
<input type="checkbox"/> Other			
DOCTOR'S SIGNATURE:			SIGNATURE:
			UC:



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: LYGEMOXPEG

(Page 2 of 3)

Date:

**** Have Hypersensitivity Reaction Tray and Protocol Available****

TREATMENT:

CHEMOTHERAPY

gemcitabine 1000 mg/m² x BSA = _____ mg

Dose Modification: _____% = _____ mg/m² x BSA = _____ mg

IV in 250 mL NS over 30 minutes on **Day 1** and **Day 8**

oxaliplatin 130 mg/m² x BSA = _____ mg

Dose Modification: _____mg/m² x BSA = _____mg

IV in 250 to 500 mL D5W over 2 hours. Flush line with D5W pre and post oxaliplatin on **Day 1**

RN to administer 250 to 1000 mL D5W concurrently with oxaliplatin infusion, titrated to reduce phlebitis discomfort for patient

pegaspargase **2500 units/m²** or **1500 units/m²** (select one) X BSA = _____ units

IV in 100 mL NS over 1 hour **OR** IM (select one) on **Day 1**

Dose Modification: _____ units/m² x BSA x _____% = _____ units

IV in 100 mL NS over 1 hour **OR** IM (select one) on **Day 1**

Note: for IM administration: volumes greater than 2 mL should be administered in 2 separate sites to reduce pain

For IV infusion: Monitor BP and vitals before and at 15, 30 and 60 minutes during pegaspargase administration; observe for 1 hour after end of infusion

For IM injection: Monitor BP and vitals, plus visual inspection of injection site before and after injection; and observe for 1 hour after injection

DOSE MODIFICATION (IF REQUIRED) ON DAY 8:

gemcitabine 1000 mg/m² x BSA = _____ mg

Dose Modification: _____% = _____ mg/m² x BSA = _____ mg

IV in 250 mL NS over 30 minutes on **Day 8**

DOCTOR'S SIGNATURE:

SIGNATURE:

UC:



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: LYGEMOXPEG

(Page 3 of 3)

Date:	
RETURN APPOINTMENT ORDERS	
<input type="checkbox"/> Return in three weeks for Doctor and Cycle _____. Book chemo on Day 1 and Day 8. <input type="checkbox"/> Last Cycle. Return in _____ week(s).	
<p>CBC and differential, platelets, creatinine, sodium, potassium, magnesium, calcium, phosphate, albumin, bilirubin (direct and indirect), ALT, alkaline phosphatase, GGT, LDH, triglycerides, amylase, lipase, random glucose, uric acid, INR, PT, PTT, fibrinogen prior to Day 1</p> <p>CBC and differential, platelets prior to Day 8</p> <p>ALT, alkaline phosphatase, GGT, bilirubin (direct and indirect), amylase, lipase, random glucose twice a week (every Monday and Thursday)</p> <p><input type="checkbox"/> If clinically indicated: EBV DNA</p> <p><input type="checkbox"/> ECG</p> <p><input type="checkbox"/> Other tests:</p> <p><input type="checkbox"/> Consults:</p> <p><input type="checkbox"/> See general orders sheet for additional requests.</p>	
DOCTOR'S SIGNATURE:	SIGNATURE:
	UC: